Noncoding RNAs in the Cardiovascular System: Exercise Training Effects by Pereira, Noemy et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
1Chapter
Noncoding RNAs in the 
Cardiovascular System: Exercise 
Training Effects
Noemy Pereira, Camila Gatto, Edilamar Menezes de Oliveira 
and Tiago Fernandes
Abstract
Exercise training (ET) represents a non-pharmacological treatment that can 
attenuate or even reverse the process of cardiovascular diseases (CVD), by stimulat-
ing protein synthesis, angiogenesis, mitochondrial biogenesis, anti-inflammatory, 
and anti-oxidative effects that are involved to enhance the performance and 
improved quality of life. Despite the benefits of exercise, the intricacies of their 
underlying molecular mechanisms remain largely unknown. Noncoding RNAs 
(ncRNAs) have been recognized as a major regulatory network governing gene 
expression in several physiological processes and appeared as pivotal modulators in 
a myriad of cardiovascular processes under physiological and pathological condi-
tions. However, little is known about ncRNA expression and role in response to 
exercise. Here we review the current understanding of the ncRNA role in exercise-
induced adaptations focused on the cardiovascular system and address their 
potential role in clinical applications for cardiovascular diseases.
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1. Introduction
Exercise training (ET) has been shown to undergo beneficial changes in 
both cardiac structure and function, protecting the heart and vessels against the 
development of cardiovascular diseases (CVD) [1–4]. CVD are a growing cause of 
morbidity and mortality throughout the world and often develop after a period of 
abnormal heart growth termed pathological cardiac hypertrophy (CH). The occur-
rence of risk factors, such as diabetes, hypertension, obesity, and advanced age 
leads to substantial complications of CVD. Loss of cardiomyocytes and capillaries 
accompanied by fibrosis contributes to decreased cardiac function ultimately lead-
ing to heart failure (HF). Although current management has improved survival in 
patients with CVD, such therapies do not fully address the underlying cause and, as 
a result, HF progresses. Thus, understanding the pathways that rescue cardiovascu-
lar remodeling (CR) and function could have important clinical implications [3–6].
Genome-wide analyses and ribonucleic acids (RNA) sequencing revealed that a 
large part of the human genome (~99%) do not encode proteins but are transcrip-
tionally active and give rise to a broad spectrum of noncoding RNAs (ncRNAs). 
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The ENCODE Project in 2000 (see https://www.encodeproject.org/), that aimed to 
characterize all the functional elements in the human genome, helped researchers 
to understand the eukaryotic genome complexity. Although ncRNAs have been 
considered as junk in the human genome, currently it represent as one of the newest 
study targets of CVD by potential role in controlling gene expression [7, 8].
Bartolomei et al. [9] discovered the first ncRNA (H19) in mice and it was one of 
the first maternally imprinted long ncRNAs (lncRNAs) to be identified [9]. Since 
then, thousands of ncRNAs have been described and are classified into two large 
groups: small ncRNAs, which are up to 200 nucleotides (nt), and lncRNAs, which 
are longer than 200 nucleotides. Small ncRNAs comprise microRNAs (miRNAs), 
PIWI interacting RNAs (piRNAs), transfer RNAs (tRNAs), and small nucleolar 
RNAs (snoRNAs). Long ncRNAs mainly refers to natural antisense transcripts and 
other lncRNAs. The discovery of the new class of RNAs increased our knowledge 
about epigenetic, transcriptional, and translational regulation of gene expression 
under physiological and pathological conditions. Thus, the possibility of ncRNAs as 
a potential tool for the treatment of CVD is of great interest [6, 8, 10–12].
ncRNAs such as miRNAs and lncRNAs are regulators of cell development, 
differentiation, and growth, exert their functions in both nuclear and cytoplasmic 
compartments. In the cardiovascular system, ncRNAs regulate cardiac develop-
ment, inflammation, hypertrophy, fibrosis, and regeneration [6, 10–12]. Beyond 
this, altered miRNA expression can be found in the blood of patients with various 
CVD [10, 13]. ET is well known to promote cardiovascular profit in which it can 
vary according to type, intensity, and duration of exercise. However, little is known 
about the regulatory interaction networks among the multiple classes of RNAs or 
the mechanisms regulated by exercise-induced ncRNAs on heart and vessel [1, 3, 
5, 14]. The contribution of ncRNAs to these adaptations has the potential not only 
to reveal novel aspects of cardiovascular system but also to identify new targets for 
prevention and treatment of the CVD.
In this review, we provide an overview of the current knowledge of the cardio-
vascular effects of ET on ncRNAs, with a specific focus on miRNAs, their role in 
regulating cardiovascular remodeling (CR) and their potential application for the 
treatment of CVD. These findings will provide insights that can aid in the develop-
ment of new therapeutic interventions for these pathologies.
2. miRNAs, a family of small ncRNAs
miRNAs, the most popular class of small ncRNAs, are a class of single-stranded, 
endogenous, conserved, RNAs (∼21–23 nucleotides) that regulate gene expression 
at the posttranscriptional level. They bind to messenger RNA (mRNA) by base 
pairing to complementary sequences within the 3′ untranslated region (3′UTR), 
and cause gene silencing through the inhibition of translation and/or degradation of 
mRNA [15–17]. However, recent studies have suggested that miRNA-binding sites 
are also located in 5′ UTRs or open reading frames (ORFs), and the mechanism of 
miRNA-mediated regulation from these sites has not been identified [18]. miRNA 
sequences are in diverse regions of the genome. Most canonical miRNAs in humans 
are encoded within introns of coding or noncoding genes. However, some miRNAs 
may be encoded by exons or may be associated in the same loci, organized as a 
polycistronic transcription unit. Small sequences and imperfect complementary, 
a single miRNA can target several to hundreds of distinct mRNAs. Conversely, 
an mRNA can be targeted by diverse miRNAs simultaneously, thus miRNAs are 
estimated to regulate the expression of more than a third of human protein-coding 
genes [15–17].
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The first miRNA, lin-4, was discovered in C. elegans in 1993. Lin-4 regulates C. 
elegans development by binding to the lin-14 mRNA to inhibit lin-14 protein expres-
sion [19]. Since then, it has been recognized that miRNAs are a highly conserved 
class of small RNAs present in most organisms and a variety of miRNAs have been 
discovered suggesting that there are in excess of 2650 mature sequences in human 
(see http://www.mirbase.org). Studies have demonstrated that miRNAs influence 
several biological events, including embryogenesis, cell death, differentiation, 
proliferation, and cell growth. Furthermore, developments in miRNA-related 
technologies, such as miRNA expression profiling and synthetic oligoRNA, have 
contributed to the identification of miRNAs involved in a number of physiological 
and pathological conditions [15, 16, 20].
The biogenesis of the miRNA starts in the nucleus; RNA polymerase II initially 
transcribes miRNAs into long segments of coding or noncoding RNA, known as 
pri-miRNAs, which are usually capped and polyadenylated. The pri-miRNAs harbor 
a local hairpin structure that is then cropped by a nuclear enzyme Drosha and their 
cofactor Pasha (also known as DGCR8) into pre-miRNAs (∼70 nucleotides). After 
nuclear processing, the pre-miRNA is exported into the cytoplasm by Exportin-5 in 
a RanGTP-dependent manner. Subsequently, the enzyme Dicer removes the termi-
nal loop of the pre-miRNAs to generate the miRNA:miRNA∗ duplex (dsRNA) of 
∼20–25 nucleotides. The dsRNA is loaded into the miRNA-associated multiprotein 
RNA-induced silencing complex (RISC), which includes the Argonaute proteins. 
One strand of the miRNA is preferentially retained in this complex and becomes 
Figure 1. 
miRNA biogenesis. miRNA genes are transcribed by RNA polymerase II (Pol II) to generate the primary 
transcripts (pri-miRNAs). The initial processing of the primary transcript is mediated by the Drosha-
DiGeorge syndrome critical region gene 8 (DGCR8) complex (also known as the microprocessor complex) 
that generates ~70 nucleotide (nt) pre-miRNAs. Pre-miRNA has a short stem plus, which is recognized by the 
nuclear export factor exportin 5. Once exported from the nucleus, the cytoplasmic RNase III Dicer catalyzes 
the production of miRNA duplexes. Dicer, TRBP (TAR RNA-binding protein; also known as TARBP2), and 
Argonaute (AGO) 1–4 mediate the processing of pre-miRNA and the assembly of the RISC (RNA-induced 
silencing complex). Within this complex, one strand of the miRNA duplex is removed resulting in a single-
stranded miRNA, partially complementary to target mRNA, which remains in the complex. miRNA complex 
interaction with mRNA induces posttranscriptional silencing through as both mRNA destabilization and 
translational repression (https://smart.servier.com/image-set-download/).
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the mature miRNA depending on its thermodynamic stability; the opposite strand, 
known as the passenger strand, is eliminated from the complex. The RISC acts as a 
guide by base pairing of miRNA with its target mRNAs, resulting in mRNA cleav-
age, mRNA deadenylation, and translation repression (Figure 1). It is well recog-
nized that pairing in the ‘seed’ region of the miRNA (nucleotides 2–7 or 8) appears 
critical for target recognition. Thus, miRNAs that bind to target mRNAs with 
imperfect complementarity repress target gene expression via translational silenc-
ing. In contrast, miRNAs that bind to their target mRNAs with perfect complemen-
tarily induce mRNA degradation [15–17, 20].
3. miRNAs regulation by long noncoding RNAs
Emerging evidences suggest that miRNAs may be affected by long noncoding 
RNAs (lncRNAs) [14, 21]. While there is plenty evidence of miRNAs involvement 
in exercise adaptations, investigations on lncRNAs are still lacking [14]. LncRNAs 
are a heterogeneous group of transcripts modulating gene expression at multiple 
and more complex levels than miRNAs. One way to classify lncRNAs is according 
to their mechanism of action: signal, decoy, guide, scaffold, enhancer, or sponge 
lncRNAs (see the review by [22, 23]).
Similar to miRNAs, lncRNAs have been shown to be involved in CVD with sev-
eral reports about their specific expression in different cardiac diseases [21, 24–30]. 
In this context, it was recently showed that H19, which is a maternally imprinted 
lncRNA, is implicated in CVD [24, 31]. H19 is highly expressed during embryogen-
esis but is strongly repressed after birth, with a significant re-expression of lncRNA 
H19 in CVD. Liu et al. [24] showed that miRNA-675 mediates the anti-hypertrophic 
effect of H19 on cardiomyocytes acting as a negative regulator of cardiac hypertro-
phy. In addition, it was demonstrated that H19 exon1 encodes miR-675-3p and miR-
675-5p, which are up-regulated in pathological CH. Prediction algorithms identified 
a pro-hypertrophic factor, Ca/calmodulin-dependent protein kinase IIδ (CaMKIIδ), 
as potential targets for miR-675-3p and miR-675-5p, which was confirmed by 
luciferase reporter gene assays [24]. Moreover, high H19 expression has been linked 
to hyperhomocysteinemia, a known risk factor for coronary artery disease [32]. 
Furthermore, H19 was reported to sponge let-7 family miRNAs, which are believed 
Figure 2. 
Cardiac disease-induced cardiac remodeling (CR) is characterized by an aberrant profile of myocardium 
growth, accompanied by fibrosis, apoptosis, and cardiac dysfunction. lncRNAs H19, CHRF, Myheart, Chast, 
and Chaer have been described to regulate pathological cardiac hypertrophy; cardiac fibroblast-enriched 
lncRNAs Meg3 and Wisper controlling cardiac fibrosis; and lncRNAs CHRF, Myheart, and Chaer associated 
with heart failure in response to cardiac injury.
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to have atheroprotective role [21, 33]. Thus, lncRNA-miRNA-mRNA axis reveals a 
promising therapeutic strategy for CVD.
Cardiac hypertrophy-related factor (CHRF) [26], myosin heavy-chain-associ-
ated RNA transcripts (Myheart) [25], cardiac hypertrophy-associated epigenetic 
regulator (Chaer) [27], cardiac hypertrophy-associated transcript (Chast) [28], 
cardiac fibroblast-enriched lncRNA maternally expressed 3 (Meg3) [29] and 
Wisp2 super-enhancer-associated RNA (Wisper) [30] are lncRNAs linked to CR 
(Figure 2). Additionally, recent gain- and loss-of-function studies, both in vitro in 
cell lines and in vivo in mouse models, have demonstrated that lncRNAs play critical 
roles in cardiovascular biology and diseases.
4. Heart, exercise, and miRNAs
4.1 Cardiac remodeling and dysfunction: exercise training effects
The mammalian heart is a muscle and is the first organ to form in the embryo. 
The development of heart is highly complex and involves the integration of mul-
tiple cell types as well as a connection between vascular system and blood vessels. 
However, its uninterrupted development and function are determinant to organism 
survival [34, 35]. The primary function of heart is to contract and pump blood 
throughout the circulatory system to deliver oxygen and nutrients to tissues and to 
transport carbon dioxide back to the lungs [36, 37]. This organ can be remodeled 
according to environmental stimuli or external stimuli.
Cardiac remodeling (CR) is an adaptation to increased cardiac overload 
including a variety of mechanical, hemodynamic, and hormonal factors that 
promotes changes in structure, dimensions, mass, shape, and functions of the 
heart as well as cardiac cells [34, 38], and has been generally defined as either 
physiological (i.e., normal) or pathological (i.e., detrimental) [34]. Physiological 
growth occurs in response to exercise, pregnancy, or postnatal growth [34] caus-
ing heart hypertrophy, which is reversible and characterized by normal cardiac 
morphology and function [39]. On the other hand, in pathological hypertrophy, 
contractile performance, for example, can be perturbed or reduced in response to 
diverse pathophysiological stimuli, which also causes the typically heart remodel-
ing, in association with increases in myocyte cell volume [36, 39]. However, it 
can slowly progressives to become maladaptive, leading to a decompensation in 
cardiac function [40].
Cardiac dysfunction is the main consequence of pathological CR, a process that 
involves a complex series of transcriptional, signaling, structural, electrophysiologi-
cal, and functional events, occurring within the cardiac myocyte and in the other 
cellular elements within the ventricle (fibroblasts, endothelial cells, T-cells, etc.). 
Thus, it starts with genetic changes in response to cardiac insults, with re-expres-
sion of fetal genes (atrial and β-type natriuretic peptide, β-myosin heavy chain, 
and α-skeletal muscle actin), fibrosis, endothelial dysfunction, and inflammation. 
Consequently, cellular and molecular changes occur, resulting in progressive loss of 
ventricular function, asymptomatic at first, that evolves to signs and symptoms of 
HF [41–43].
ET is the most effective non-pharmacological intervention to prevent or reduce 
cardiovascular disturbances [2, 44]. ET can be classified as static or dynamic and 
leads to two different types of intermittent chronic cardiac overload, which induces 
morphological changes in the heart [45]. This changes will depend on factors such 
as the type of exercise used (aerobic or resistance), volume (training time), inten-
sity (degree of training load), and frequency of ET (number of training session 
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at any given time) [2, 45], and is directly related to maximal aerobic capacity or 
VO2 max [42]. It is known that ET is one of major stimuli for physiological cardiac 
hypertrophy (CH) [46]. The main physiological responses attributed to CR are 
the increase in contractility, the improvement of the transient Ca2+ intracellular, 
increase in expansion with significant improvements in myocardial oxygenation, 
and additional endothelium-dependent functions that prevent ischemic events [42].
In contrast to pathological CH that occurs in response to continuous stimulus 
on heart (arterial hypertension, valve disease, or aortic stenosis, for example), CH 
induced by ET consists of a frequent, but intermittent stimulus cardiac hemody-
namic overload [2]. Thus, a pressure overload in response to resistance training, for 
example, causes an increase in the width of the cardiac myocytes without dilation 
of the chamber and causes a concentric left ventricle (LV) hypertrophy [39]. On the 
other hand, the increase in size of cardiomyocytes by aerobic ET is mainly associ-
ated with an eccentric LV hypertrophy phenotype, induced by volume overload, 
with predominant myocyte growth in series, promoting dilation of the cardiac 
chamber. Either concentric or eccentric CH by ET is not followed by fibrosis and 
re-expression of fetal genes, which is linked to preserved or improved cardiac 
function [39, 44].
Medeiros et al. [47] showed that CH induced by moderate aerobic ET causes 
resting bradycardia in rats by an increase in cardiac vagal activity, which is associ-
ated to increased VO2 peak [44, 47, 48] and an increase in nitric oxide (NO) and 
angiogenesis levels in heart of experimental animals. The increased cross-sectional 
area in the heart contributes to the increase in ventricular systolic volume and 
cardiac output, which improves aerobic capacity [49]. Thus, ET has been widely 
used as a preventive therapeutic strategy for prevention or treatment of diseases 
in cardiovascular system. However, the underlying molecular mechanisms that 
regulate ET responses have not been fully elucidated, especially with regard to 
CH [50]. In this sense, emerging evidences have shown that miRNAs may play an 
important role in both heart development and CR [44, 51] as in the pathogenesis 
of HF through their ability to regulate the expression levels of genes that govern 
the process of adaptive and maladaptive CR [52]. Besides, miRNAs can mediate the 
beneficial effects of ET in heart in both physiological and pathological CR well as in 
cardiac disorders [2, 53, 54].
Therefore, in the below section we will highlight the role of miRNAs in both 
physiological CR well as diseased heart. In another section, we will highlight what is 
known until now about the effects of ET in the regulation of miRNA expression in 
heart in these different scenarios.
4.2 miRNAs in cardiac remodeling and heart diseases
The miRNAs may be essential regulators in the development and normal physi-
ology. Dysregulation of miRNA expression has been found to correlate with CR and 
disease in both human and mouse [55, 56]. Therefore, identification of a signature 
of miRNAs is an essential and promising prerequisite for the study of the biological 
functions of this class of molecules in the cardiovascular system [57, 58].
A single miRNA can be highly expressed in one tissue and may not have, or 
have a low expression in another [58]. In this sense, miRNA-1, -133, -206, and -208 
are muscle specific and are primarily expressed in the cardiac and skeletal muscle 
[57, 59], with miRNA-208 being solely expressed in heart [57]. During cardiac 
development, the expression of miRNA-1 increases, which promotes a decrease in 
levels of the heart and neural crest derivatives expressed 2 levels (Hand2), a gene-
target, reaching it at the levels found in mature cardiac myocytes [57]. miRNA-1 
also promotes myogenesis, targeting the histone deacetylase 4 (HDAC4). The 
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miRNA-1 family represents more than 40% of all the miRNAs expressed in the 
heart [60], which consists of a subfamily composed of miRNA-1-1, miRNA-1-2 and 
miRNA-206.
The miRNA-133 family consists of the subfamily miRNA-133a-1, 133a-2, and 
133b. miRNA-133, like miRNA-1, also plays an important role in cardiac develop-
ment. In fact, the deletion of miRNA-133 results in severe cardiac malformations, 
together with embryonic and post-natal lethality, as a consequence of an insuffi-
cient number of cardioblasts [57].
The miRNA-208a, -208b, and -499 are specifically encoded by introns of Myh6 
(α-MHC), Myh7 (β-MHC), and Myh7b, respectively. In mice, Myh7/miRNA-208b is 
expressed in the embryonic heart and Myh6/miR-208a is expressed predominantly 
in the postnatal stages. Myh7 is re-expressed in the adult’s heart only after cardiac 
stress. Myh7b/miRNA-499 is expressed in the embryonic heart and in the adult 
heart [61]. However, the targeted deletion of miRNA-208a in mice results in only 
a mild cardiac phenotype, such as the ectopic expression of rapid muscle markers 
of the skeleton and the impaired ability to respond to postnatal stress. Therefore, 
this scenario suggests a not so essential role of these three miRNAs during cardiac 
development [51, 62].
Considering the importance of miRNAs even in heart development, it is under-
standable that dysregulation in its expression is implicated in a variety of patho-
logical disorders, including diabetes, various cancers, and CVD [51]. Pathological 
CH, unlike the physiological CH promoted by ET, is a common response to various 
cardiac disorders, which includes not only hypertension, but also cardiac ischemic 
disease, valvular diseases, and endocrine disorders, and is therefore, considered the 
major determinant of mortality and morbidity in CVD [58, 63]. Currently, existent 
literature suggest that mainly miRNA-1, -18b, -21, -133, -195, and -208 play impor-
tant roles in modulating CH [52].
In this sense, Carè et al. [64] found a decrease in expression of both miRNA-
133 and miRNA-1 in three different animal models of CH, including hypertrophy 
induced by pressure overload, hypertrophy induced by Akt overexpression, and 
adaptive CH in mice and humans [64]. However, in vitro overexpression of these 
miRNAs inhibited hypertrophy, while in vivo inhibition of miRNA-133 promoted 
a pronounced and sustained CH. In this same study, three new specific targets 
for miRNA-133 have been identified, which include RhoA and CH regulatory 
GDP-GTP exchange protein; the Cdc42, a signal transduction kinase implicated in 
hypertrophy; and Nelf-A/WHSC2, a nuclear factor involved in cardiogenesis [64]. 
miRNA-1, in turn, controls cardiac myocyte growth by negatively regulating the 
expression of calcium-calmodulin signaling components, Mef2a and Gata4, which 
are key transcription factors that mediate calcium-dependent changes in gene 
expression [65].
Cheng et al. [55] showed that miRNAs are aberrantly expressed in culture of 
neonatal cardiomyocytes stimulated with angiotensin II or phenylephrine, and 
that miRNA-21 knockdown exerts a negative effect on cardiomyocyte hypertrophy 
in vitro. The mitogen-activated protein kinase (MAPK), FasLigand (FasL), and 
homolog of deleted phosphatase on chromosome 10 (PTEN) are targets that have 
already been validated for miRNA-21, which stimulate the Akt pathway [66, 67]. In 
addition, there is evidence that depletion of miRNA-21 exerts anti-apoptotic and 
pro-proliferative effects on rat proliferative vascular smooth muscle cells (VSMCs) 
[68]. On the other hand, overexpression of miRNA-1 (which was aberrantly down-
regulated in induced-hypertrophy model in mouse), prevented the hypertrophic 
growth of cardiac myocytes that were stimulated by endothelin-1 [67].
Cardiac fibrosis is an important contributor for the development of cardiac dys-
function in diverse pathological conditions, such as myocardial infarction (MI), 
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ischemic, dilated, hypertrophic cardiomyopathies, and HF and can be defined as 
an inappropriate accumulation of extracellular matrix proteins in the heart [69]. 
The exacerbated expression of extracellular matrix proteins is determinant in the 
differentiation between physiological and pathological CH [2]. In this sense, the 
negative regulation of miRNA-29 with anti-miRNAs in vitro and in vivo in a MI 
model induces the expression of collagens, whereas miRNA-29 overexpression in 
fibroblasts reduces this expression, suggesting this miRNA as a regulator of cardiac 
fibrosis [46]. Currently, the miRNA-29 family has been validated as a regulator 
of the gene expression of collagen I, III, fibrillin I, and elastin and is involved in 
pathological CH and the HF process [46, 51, 66]. In addition, decreased expres-
sion of the miRNA-29 family, miRNA-24, and miRNA-320 occurs after MI, and 
the decrease in miRNA-29 expression promotes fibrosis and scar formation in the 
heart [51].
Through microarray analysis, van Rooij et al. [56] related the miRNAs found 
both in response to hypertrophy and HF and identified more than 12 miRNAs 
dysregulated in the heart of mice. Many of these miRNAs were similarly regulated 
in failing human hearts. Interestingly, overexpression of miRNA-23a, miRNA-23b, 
miRNA-24, miRNA-195, or miRNA-214 induced hypertrophic growth in cardio-
myocyte culture, whereas overexpression of miRNA-150 or miRNA-181b decreased 
cell size of the cardiomyocyte. The miRNA-23a knockdown attenuated hypertrophy 
[56] and the overexpression of miRNA-195 in vivo alone (transgenic mouse), was 
sufficient to lead to hypertrophy and HF [56]. The miRNA-23a is transcriptionally 
regulated by the nuclear factor of activated T cells, cytoplasmic 3 (NFATc3), which 
mediates the signaling pathway of cardiac stress. Thus, miRNA-23a overexpression 
can triggers a hypertrophic response by means of its target-gene muRF1 (muscle 
specific ring finger protein 1), an anti-hypertrophic protein, while negative regula-
tion of miRNA-23a abolishes CH induced by isoproterenol in mice [70]. Other 
miRNAs exhibited pro-hypertrophic profile, including miRNA-208, -21, -18b, -27, 
and -9 [56].
Transgenic overexpression of miRNA-208a in the adult heart of mice is enough 
to induce hypertrophic growth, resulting in pronounced repression of regula-
tory target-genes, such as THRAP1 and myostatin (negative regulators of muscle 
growth and hypertrophy). In contrast, the deletion of cardiac miRNA-208a protects 
these animals from CH in response to hemodynamic cardiac stress by canceling 
the re-expression of fetal gene β-MHC [71]. In addition, therapeutic inhibition of 
miRNA-208 (by subcutaneous delivery of anti-miRNA-208a) reduces deleterious 
CR, improves cardiac function, and survival during HF in hypertensive rats [72]. 
Curiously, inhibition of cardiac-specific miR-208a may have therapeutic usefulness 
in a variety of metabolic disorders, such as obesity and type-2 diabetes in the setting 
of cardiac dysfunction by targeting and increasing MED13 in heart [73].
miRNA-199a is predominantly expressed in cardiomyocytes, where it maintains 
cell size and may play a role in the regulation of CH [56]. miRNA-199 is down-
regulated under hypoxic conditions in cardiac myocytes (SIRT1) and hypoxia-1α 
inducible factor (HIF-α), an essential transcription factor for induction of the gene 
network of response to hypoxia. Thus, miRNA-24, miRNA-29, miRNA-199, and 
miRNA-320 represent potential therapeutic targets for ischemic injury in cardiac 
myocytes [51].
An overexpression of miRNA-22 was sufficient to induce pathological CH [74], 
showing itself as an essential miRNA for this process. On the other hand, the silenc-
ing of miRNA-22 in the heart of mice abolished CH and remodeling in response to 
two independent stressors: the infusion of isoproterenol and the activated calci-
neurin transgene. In addition, SIRT1 and HDAC4 were validated as target genes 
for miRNA-22 in the heart [74]. miRNA-155 is also required for the development 
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of CH in response to stress. In fact, the knockout of miRNA-155 in mice suppresses 
pathological CR, in addition to preventing the progression of HF [75].
The miRNA-34 family (miRNA-34a, -34b, and -34c) expression levels are 
elevated in both hearts of mice with cardiac stress and in aging process, as well as 
in patients with HF [76, 77]. In this way, inhibition with antimiR-34a/antimiR-34 
has emerged as a promising therapeutic strategy [78]. miRNA-34a appears to be 
an essential regulator in cardiac repair and regeneration after MI in the heart. In 
fact, in a study by Yang et al., miRNA-34a mimic delivery limited cardiomyocyte 
proliferation and subsequent MI recovery in mice, whereas antimiR-34a treatment 
improved remodeling post infarction. Furthermore, in isolated cardiomyocytes, 
miRNA-34a directly regulated cell cycle activity and death, via modulation of its 
targets, which include Bcl2, Cyclin D1, and SIRT1 [79]. Thus, at first, modulation of 
miRNA-34a appears to be important in the process of repairing adult myocardium 
after injury. The study conducted by Baker et al. showed that miRNA-34a is induced 
by oxidative stress (OE) in patients with chronic obstructive pulmonary disease, 
reducing the gene expression of SIRT1 and SIRT6 in bronchial epithelial cells [80]. 
Thus, miRNA-34a antigens may have therapeutic potential in several pathological 
conditions, including CH.
In addition, Bernardo et al. [76] showed that only the inhibition of the whole 
miRNA-34 family, but not the inhibition of miRNA-34 alone, improves cardiac 
function in mice with preexisting hypertrophy induced by TAC and also attenuates 
the pathological remodeling of the LV after MI [76]. In this same work, four targets 
for miRNA-34 (vinculin, Sema4b, Pofut1, and Bcl6) were validated, which were 
positively regulated and associated with the cardiac protection found in both TAC 
and/or MI mice treated with the antimiR-34 LNA. Thus, the authors believe that, 
since LNA-based therapies have already entered clinical trials, inhibition of the 
entire miRNA-34 family has great therapeutic potential.
Therefore, it is clear that miRNAs play pivotal roles in cardiovascular develop-
ment and disease [51, 56]. Recent evidences show that miRNAs are dynamically 
regulated by exercise [1, 54, 81]. Thus, the elucidation of the relationship between 
ET and miRNAs in heart in physiological and pathological (i.e., hypertension, HF, 
spinal cord injury, etc.) conditions is fundamental to understand how exercise 
regulates the cardiovascular system at the molecular level, which may be promising 
for the development of new drugs [2].
4.3  miRNAs regulation by exercise training in cardiac remodeling and heart 
diseases
The miRNA-1 and miRNA-133 are decreased in both aerobic treadmill-induced 
physiological hypertrophy and pressure overload-induced pathologic hypertrophy 
[64]. Additionally, swimming training is recognized for its efficiency in inducing 
myocardial hypertrophy and a significant increase in LV end-diastolic volume in 
rats [82]. In study conducted by Soci et al. [66], female rats were submitted to two 
swimming protocols (one moderate and other with high volume training to mimic 
an active individual and an elite athlete, respectively) for 10 weeks and developed 
physiological CH in a proportional way to the training volume. It was associated to a 
down regulation of miRNAs-1, -133a, and -133b in LV of trained rats also compared 
to sedentary group, which is inversely proportional to the physiological CH [66]. 
These results suggest that these myomiRs can be regulated by exercise, regardless of 
type (running or swimming) or volume (moderate and high) training, maintaining 
a similar expression profile [1]. Besides, Ma et al. [49] found that CH in rats induced 
by swimming exercise correlates with the modulation of other miRNAs, including 
miRNA-21, miRNA-124, miRNA-144, and miRNA-145 [49]. These miRNAs have as 
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validated targets Pik3a, PTEN, and TSC2, which are negative regulators of the PI3K/
AKT/mTOR signaling pathway. Importantly, Liu et al. [5] showed that the inhibi-
tion of miRNA-222 in vivo completely blocked cardiac and cardiomyocyte growth 
in response to exercise while reducing markers of cardiomyocyte proliferation. 
Indeed, the authors revealed that miRNA-222 delivery was sufficient to protect the 
heart against dysfunction and adverse remodeling after ischemic injury [5].
In the same work cited before, Soci et al. [66] found an increase in miRNA-29c 
expression in LV in response to swimming training, which was inversely corre-
lated with a decrease in both collagen I and III expression as well as in OH-proline 
concentration, being essential for the improvement of LV compliance observed in 
rats [66]. These findings exhibit an important integrative and regulatory role for 
miRNAs in the fibrotic response of trained heart.
Other work from our group showed that swimming training also causes an 
increase in miRNA-126 in the heart of rats, targeting and decreasing in expression 
of Spred-1, which contributes to angiogenesis in this tissue [83]. Although Pi3kr2 
is also a well-validated target for miRNA-126, it was not altered by the swimming 
protocol. Physiological CH also involves the regulation of some miRNAs related to 
increased expression of angiotensin receptor-1 (AT1R), regardless of the participa-
tion of Ang-II. In parallel, increased angiotensin-converting enzyme 2 (ACE2), 
angiotensin (1–7), and Ang-II receptor in heart, suggest that miRNAs are involved 
in the regulation of the non-classical renin-angiotensin-aldosterone system 
(RAAS), counteracting the classic cardiac RAAS in CH [2, 54]. Fernandes et al. 
[54] evaluated that swimming alter the expression of cardiac miRNAs targeting the 
components of the RAAS, which were associated with the development of ventricu-
lar CH in rats [54]. In fact, swimming training increased the expression of miRNAs-
27a and 27b by targeting the angiotensin-converting enzyme (ACE) and decreased 
miRNA-143 expression by targeting ACE2 in the heart of healthy rats.
Differently from which is found in pathological CH [61], high volume ET 
decreases the expression of cardiac miRNA-208a in healthy, induces the upregula-
tion of targets such as THRAP-1, Purβ, and Sox6, and improves the balance between 
βMHC and αMHC gene expression [2, 84]. In addition, in recent study, Fernandes 
et al. [85] showed that aerobic ET prevents weight gain and pathological CH in 
obese Zucker rats, via increase of cardiac MED13 by regulation of miRNA-208. 
Thus, miRNA-208 represents a potential potent therapeutic target for modulation 
of cardiac function and remodeling during progression of heart disease.
In addition, the study conducted by Fernandes et al. [86] showed that swim-
ming training reestablishes the peripheral levels of the -16, -21, and -126 miRNAs 
associated with revascularization in hypertension. This alteration was accompanied 
by normalization of vascular endothelial growth factor (VEGF), endothelial nitric 
oxide synthase (eNOS), and phosphatidylinositol-3 kinase regulatory subunit 
(PI3KR2) in parallel to a normalization of pro-apoptotic (Bad) and anti-apoptotic 
mediators (Bcl-2, Bcl-x, and p-Badser112: Bad ratio) [86].
Swimming ET restores the miRNA-29a and miRNA-29c levels of the heart 
and prevents the deposition of type I and III collagen in the border zone as well 
as in remote regions of the infarcted myocardium of rats, which can contribute 
to the improvement of the ventricular function induced by the aerobic training 
[87]. Cardiac fibrosis, which impairs cardiac contractility, is a major aspect of the 
remodeling process after MI. Impaired cardiomyocyte contractility and calcium 
transient are hallmarks of LV contractile dysfunction [88]. In this sense, Melo 
et al. [81] showed that moderate aerobic ET also restores cardiac Ca2+ transient 
after MI, regulating miRNA-1 and miRNA-214 levels [81]. Additionally, resistance 
training has been shown to induce CH, with improved cardiac function of isolated 
cardiomyocytes, which is partially explained by the decrease of miRNA-214 and 
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the increase of gene SERCA2a expression [81]. There are few studies that demon-
strate the protective role of resistance training in heart through changes in miRNA 
expression pattern. Thus, there is a potential role of these miRNAs in promoting 
cardioprotective effects on CR.
5. Vascular, exercise, and miRNAs
The vascular disease in its various forms is one of the leading causes of 
death worldwide, and in accordance with the projection of the World Health 
Organization, this number only increases in the next 30 years [89]. ET prevents 
the progression of vascular diseases and reduces cardiovascular morbidity and 
mortality. ET also ameliorates vascular changes including endothelial dysfunction 
and arterial remodeling and stiffness, usually present in type 2 diabetes, obesity, 
hypertension, and metabolic syndrome [90].
Although there are major advances in the surgical area, the great challenge that 
anyone who presents a framework of CVD remains the prevention of this disease. 
Currently, there are some ways to alleviate this disease such as the use of beta-block-
ers, ACE inhibitors, statins; all these strategies are for mitigate the risk factors such 
as hypertension and dyslipidemia. Already in more severe cases, surgical procedures 
such as coronary artery bypass grafting, angioplasty (in severe cases of atheroscle-
rosis), and others are performed [91–93].
Despite these strategies of mitigate the risk factors, this is still not enough since 
the rate of individuals affected and morbimortality has been increasing in relation 
to this class of diseases. So, the search for new therapies and approaches to prevent 
the onset and reduce the progression of vascular disease is desperately needed. 
Therefore, the processes time consuming since the mechanisms involved in this 
disease are not yet fully understood.
Atherosclerosis is the main cause of CVD. This is a chronic inflammatory 
disease that affects the blood vessels and arteries of medium or large size, usually 
in the areas of bifurcation, due to the non-laminar flow, leading to an endothelial 
dysfunction due to chronic exposure to pro-inflammatory molecules, and also to an 
inhibition of anti-inflammatory molecules, such as NO, this causes a narrowing of 
the arterial lumen due to atheroma plaque, impeding blood flow [94, 95].
In this disease, the blood flow changes from laminar to turbulent, due to the 
narrowing of the vascular lumen, the endothelial cells (EC) respond to this flow, 
that is, to the shear stress, this response is due to mechanosensors genes present on 
the cell surface and also the activation of the adhesion molecules and other inflam-
matory cytokines that are activated to alleviate the excess of cholesterol low-density 
lipoprotein (LDL) that is encompassed in the vascular intima [96–98].
Another important factor that has been widely studied in vascular diseases and 
in atherosclerosis are the miRNAs, which can regulate the cellular phenotype of 
both VSMCs and EC, such as the proliferation, migration, and cell growth, and can 
also regulate the handling of lipids and inflammatory molecules [99–101].
5.1 miRNA-126
miRNA-126, for example, can regulate both inflammation and angiogenesis (the 
process of new vessel formation). This miRNA is basically expressed in platelets and 
EC, which in turn play an important role in the blood circulation, as well, regulating 
vascular tone, recruitment of other cells, and even vascular homeostasis [102, 103], 
and the transcription of this miRNA is regulated by the transcription factor Ets1, 
which is known for their role in specific gene expression in EC [104]. Harris et al. 
Muscle Cells - Recent Advances and Future Perspectives
12
[104] demonstrated that miRNA-126 negatively regulates the vascular cell adhesion 
molecule (VCAM-1). This protein mediates the adhesion of lymphocytes, mono-
cytes, eosinophils, and basophils of the vascular endothelium, thus interfering with 
the adhesion of leukocytes induced by tumor necrosis factor (TNF) in the endothe-
lium, which may decrease leukocyte infiltration in the vascular wall and also in the 
interaction of leukocytes with EC [104].
This miRNA can influence the reduction of apoptotic cells contained in the vascu-
lar thrombus, softening the inflammatory reaction characteristic of atherosclerosis; 
so the miRNA-126 has an anti-atherosclerotic effect, which is also related to the G 
16 protein signaling regulator, which results in recruitment of circulating progeni-
tor cells, leading to stabilization of atherosclerotic plaque [105, 106]. Studies show 
that on deletion of this miRNA, vascular integrity decreases; in the case of infarcted 
individuals, a defect in cardiac neovascularization occurs [107].
This miRNA may be pro-angiogenic because of its binding to the PI3K path-
way, which is important in regulating mitogenesis, cell differentiation, and 
insulin-stimulated glucose transport, and mitogen-activated protein kinases 
(MAPKs) that respond to extracellular stimuli and regulate various cellular 
activities such as gene expression, mitosis, differentiation, cell survival, and 
apoptosis. PI3K pathway promotes the suppression of the sprouty-related EVH1 
domain containing protein-1 protein (Spred-1) that generally inhibits the signal-
ing pathway [108–111].
Recent studies showed that the miRNA-126 levels in the circulatory system 
increase to varying degrees after different ET protocols [1]. It is already known that 
regular aerobic exercise has a positive effect on arterial endothelial function, mainly 
by increasing circulating NO and reducing endothelin-1. Aerobic exercise can also 
improve vascular endothelial and mitochondrial function to protect blood vessels, 
thus reducing the incidence of CVD [83, 112, 113].
Recent study demonstrated that the plasma levels of miRNA-126 were increased 
in obese subjects after an acute aerobic exercise session [114] Already noted 
that improvement of vascular endothelial function in adolescents after 6 weeks 
of aerobic exercise combined with dietary control may be related to changes in 
serum level miRNA-126, this improved peripheral vasodilator capacity, indirectly 
reflecting the improvement of vascular endothelial function in obese adolescents 
[115]. This increase of serum levels of the miRNA-126 through ET represents the 
beneficial aspects for obese individuals and associated diseases such as CVD. This 
may be related to the increase of NO provided by physical training, which is already 
well established in the literature, that aerobic exercise increases the expression and 
phosphorylation of endothelial nitric oxide synthase (eNOS) and with that the 
levels of oxidative stress decreased, leading to an increase in the use of NO and an 
increase in vascular function [90, 102, 116–118].
5.2 miRNA-21
miRNA-21 regulates cell proliferation through your gene target PTEN, which is a 
protein that acts as phosphatase and operates primarily on dephosphorylation in the 
PI3K/Akt signaling pathway. PTEN suppresses Akt signaling, which decreases the 
activity of eNOS and PTEN also inhibits the expression of VCAM-1 in EC stimu-
lated by TNF-α [119]. A pathological condition that increases the expression of the 
miRNA-21 is shear stress in your state turbulent flow [120]. miRNA-21 also contrib-
utes to phenotypic change in EC, which is induced by transforming growth factor β 
(TGF-β) [121]. These data indicate that miRNA-21 modulates vascular homeostasis 
through PTEN and Akt.
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Although miRNA-21 has been involved in promoting the proliferation of 
VSMCs in response to a series of models of vascular mechanical injury, its 
role remains to be defined in the formation of atherosclerotic lesion [68]. 
miRNA-21 also mediates VSMC differentiation from the contractile phenotype 
to the synthetic through TGF-β and BMP signaling in a single posttranscriptional 
processing step, implying that Smad proteins can control the maturation of 
miRNAs [122].
It was demonstrated by [86] that aerobic ET has a beneficial effect on the 
regression of arterial hypertension, restoring the normal expression of miRNA-16, 
-21, and -126 of skeletal muscle microcirculation, normalization of levels of VEGF, 
eNOS, and PI3KR2, as well as proapoptotic (bad) and antiapoptotic mediators 
(Bcl-2, Bcl-x, and p-Badser112: Bad ratio), indicating that the balance between 
angiogenesis and apoptotic factors that can prevent microvascular abnormalities in 
rats hypertensive, demonstrating once again the protective effect of aerobic physi-
cal training.
5.3 miRNA-221/222
The miRNA-221/222 is expressed in EC, VSMCs, and hematopoietic cells. It 
has been shown that the endothelial progenitor cells of patients with coronary 
artery disease have an increased expression of these miRNAs, these cells have a 
factor important in endothelial integrity and vascular repair [123]. One of the 
target genes of these miRNAs is signal transducer and activator of transcription 
5A (Stat5A), a transcription factor involved in the regulation of cell prolifera-
tion and migration, it has been identified that Stat5A is negatively regulated by 
miR-222 and it has been observed in EC of atherosclerotic lesions that Stat5A is 
low expression, so it is possible that Stat5A may be a new therapeutic target for 
 atherosclerosis [103, 123, 124].
The study by Liu et al. [123] also demonstrated that miRNA-221/222 has oppo-
site biological functions depending on the cell; the study observed that inhibition of 
miRNA-221/222 is able to increase reendothelization, whereas in VSMC neointimal 
formation was significantly reduced. Thus, miRNA-221/222 could be an ideal 
therapeutic target in patients with atherosclerosis, angioplasty, stent implantation, 
or myocardial revascularization surgery [123].
5.4 miRNA-146a
The increased expression of the miRNA-146a has been observed in vascular 
injury after balloon angioplasty. This miRNA can mediate cell-to-cell communica-
tion between VSMCs and CE and also other cell types in the vessel wall [125]. A 
study by Sun et al. [126] attested that transcription of miRNA-146a is regulated by 
the transcriptional factors KLF-4 (Krüppel-like factor 4) and KLF-5 (Krüppel-like 
factor 5) and they play an important role in promoting proliferation of VSMCs 
(in vitro) and when the carotid artery is injured with a balloon catheter there 
occurs a hyperplasia of the neointima (in vivo) [126]. Ji et al. [68] also found an 
increase in miRNA-146a in injured arteries, resulting in a remarkable formation of 
neointima. In this study, the expression of several miRNAs in the wall of the vessel 
after angioplasty was observed for the first time [68]. In the study by Chen et al. 
[127], several miRNAs have been shown to play roles such as proliferation, cell 
differentiation, and apoptosis in the inflammatory responses of monocytes and 
macrophages with stimulation of oxidized LDL that are primordial in the develop-
ment of atherosclerosis [127].
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Cao et al. [128] observed that levels of miRNA-146a and miRNA-21 were 
increased in atherosclerotic plaques and that these miRNAs suppress the expression 
of Notch2 (neurogenic locus notch homolog protein) which is a membrane protein, 
and Jag1 (Jagged1) is a cell surface protein [128]. These provide important negative 
feedback on the proliferation of VSMCs in response to vascular injury, so inhibitions 
of these miRNAs may present a new strategy for the prevention of fibroproliferative 
vascular diseases.
5.5 miRNAs-143/145
The miRNAs-143/145 have an important role in the differentiation of VSMC 
as well as miRNA-146a, with a critical role in cell phenotype change [129, 130]. 
Boettger et al. [130] demonstrated that the detection of miRNA-143 and miRNA-
145 altered the VSMC phenotype from contractile (physiological) to synthetic 
(pathological), in which this led to neointimal formation in elderly mice [130]. 
Another study highlighted the suppression of these miRNAs in human aneurysms 
[131]. Several targets of miRNA-143 and miRNA-145 have been reported in which 
they regulate the functions of VSMCs, for example, the transcription factors KLF-4 
(Krüppel-like factor 4), myocardin, Elk-1 (ELK1, ETS member of the family of 
oncogenes), and KLF5. In addition, the ACE has been shown to contribute to 
vascular tonus dysregulation and to reduce blood pressure in mice with high expres-
sion of miRNA-143/145 [129, 130]. Thus, these miRNAs through their targets are 
antiatherosclerotic and have the function of regulating the phenotype of the VSMCs 
and inhibit the formation of neointima.
5.6 Others miRNAs
Other miRNAs are also involved with EC and VSMCs like miRNA-27b and 
let-7. Kuehbacher et al. [103] demonstrated that inhibition of miRNA-27b and 
let-7f in the EC significantly reduced the onset of the endothelium, therefore 
when these miRNAs are with increased expression, it is suggested that it has a 
pro-angiogenic action [103]. It has also been observed that shear stress increases 
the expression of miRNA-27b supporting an activity endothelial protection [132]. 
Other miRNA vascular protector is the miRNA-296 which regulates directly the 
substrate of tyrosine kinase regulated by the hepatocyte growth factor (HGS), a 
protein responsible for the degradation of pro-angiogenic receptors VEGFR2 and 
PDGFRβ, promoting angiogenesis [133, 134]. The miRNA-130a was also identi-
fied as angiogenic, targeting the homeobox anti-angiogenic GAX (homeobox-
stop-growth), and HoxA5 proteins. It has been observed that miRNA-130a 
antagonizes the inhibitory effects of GAX on the proliferation, migration, and 
formation of EC [135].
That said, miRNAs are important regulators of vascular cell functions and 
contribute to many vascular diseases, such as coronary artery disease and, in 
general, atherosclerosis. It is supposed that the human genome encodes several 
miRNA genes, but only a few vascular-specific miRNAs have been identified so far. 
In addition, there is only some information about its specific functions of the cell 
type and target genes. Many studies have revealed an aberrant miRNA expression 
profile under pathological conditions. Thus, miRNAs can be used as new biomark-
ers and, on the other hand, may represent powerful new therapeutic targets. Several 
miRNA-based therapeutic strategies are used to modify miRNA expression as 
therapeutic approaches; one of miRNA modulators is physical training, as already 
mentioned in miRNAs-126 and 21.
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6. Conclusions
ET, especially aerobic exercise, plays a protective role in the cardiovascular 
system and has been used as a non-pharmacological therapeutic tool for the pre-
vention and treatment of CVD. Although much knowledge already exists, there is 
insufficient evidence to establish a direct link between epigenetic modulations and 
changes, caused by exercise, in the heart and blood vessels [42]. There is currently 
evidence that the protective effects of aerobic ET involve changes in pattern expres-
sion of specific miRNAs by positively regulating cardiovascular remodeling. In fact, 
miRNAs play important roles in the regulation of distinct processes in mammals, 
and although they exhibit limited complementarity with their target RNAs, it is still 
sufficient for them to regulate various physiological processes, including cell pro-
liferation, differentiation, migration, angiogenesis, apoptosis, tissue development, 
and remodeling [14, 136, 137]. However, new studies to understand the pathways 
and mechanisms in which the ET acts on the miRNAs are required. Thus, studies 
with miRNAs hope to broaden the perspective of its use in the correction of patho-
logical processes from miRNAs therapy, contributing as a therapeutic intervention 
in cardiovascular damages as well as for the survival and quality of life of patients.
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